BPA Biosante Pharmaceuticals

BioSante Pharmaceuticals (AMEX: BPA) today announced that BioSante management will present a corporate overview and update at upcoming conferences. The conferences are: The Flaherty Financial News & Wall Street Research Small Cap Conference on August 14, 2007 at 10:20 a.m. local time at the Penn Club of New York. The RedChip Small-Cap Investor Conference on August 16, 2007 at 11:00 a.m. and the Keynote address at 12:30 p.m. local time at the Waldorf-Astoria Hotel New York. The Noble Financial TWO DOUBLE-O-SEVEN conference on August 20, 2007 at 1:00 p.m. local time at the Orient Express Hotel in Charleston, South Carolina. A live audio webcast of BioSante�s presentation at the RedChip and Noble conferences can be accessed on the internet by visiting www.biosantepharma.com. An archive of these presentations will be available at the same address. These conferences each feature companies presenting to a diverse group of investors, portfolio managers and analysts interested in the biotechnology and pharmaceuticals sectors as well as industry representatives. About BioSante Pharmaceuticals, Inc. BioSante is developing a pipeline of hormone therapy products to treat both men and women. These hormone therapy products are gel formulations for transdermal administration that deliver bio-identical estradiol and testosterone. BioSante's lead products include Elestrin� (estradiol gel) developed through FDA approval by BioSante indicated for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, marketed in the U.S.�by Bradley Pharmaceuticals, Inc., BioSante's licensee, and LibiGel� (transdermal testosterone gel) in Phase III clinical development by BioSante for the treatment of female sexual dysfunction (FSD). Also in development is Bio-T-Gel�, a testosterone gel for male hypogonadism, and an oral contraceptive in Phase II clinical development using BioSante patented technology. The current market in the U.S. for estrogen and testosterone products is approximately $2.5 billion and for oral contraceptives approximately $3.0 billion. The company also is developing its calcium phosphate nanotechnology (CaP) for novel vaccines, including hepatitis B, avian flu and biodefense vaccines for toxins such as anthrax, as well as a system for delivering drugs via alternative routes of administration and for aesthetic medicine. Additional information is available online at www.biosantepharma.com.